Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 9, 2015-09 ,pp. : 868-877

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes

By Buysman Erin   Conner Christopher   Aagren Mark   Bouchard Jonathan   Liu Fang  

Current Medical Research and Opinion, Vol. 27, Iss. 9, 2011-09 ,pp. : 1709-1717

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 11, 2015-11 ,pp. : 1056-1064

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine*

By Fabunmi Rosalind   Nielsen Loretta L.   Quimbo Ralph   Schroeder Brock   Misurski Derek   Wintle Matthew   Wade Ron  

Current Medical Research and Opinion, Vol. 25, Iss. 3, 2009-03 ,pp. : 777-786

Informa Healthcare

Access to resources Recommend Favorite

Therapeutically interchangeable? A study of real‐world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 3, 2015-03 ,pp. : 245-253

John Wiley & Sons Inc

Access to resources Recommend Favorite